We aim to promote awareness and knowledge of stroke in the general population and enhance collaboration between primary care services and hospital departments. We also want to predict those patients at high-risk for first stroke by the determination of novel risk factors or markers.
We really believe that biochemical markers of stroke, will really open “a window to the brain…”. In fact, in this research line we aim to answer relevant clinical questions through the use of biomarkers: to predict stroke risk, to make stroke diagnosis and differentiate subtypes, to establish evolution and prognosis and to use biomarkers as treatment end-points.
New therapies beyond the hyperacute phase of stroke would be needed to permit the treatment of much more patients in later phases of this devastating disease. Restore the cerebral blood flow and promote neuroregeneration. To achieve these major goals, both spontaneous angiogenesis and neurogenesis need to be enhanced in the ischemic brain.
CAA, the most common form of CAA (defined by the deposition of amyloid in vessel walls of the central nervous system) is associated with amyloid-β (Aβ) deposition, particularly in elderly individuals and in patients with Alzheimer’s disease (AD).